> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# ADAR1's Private Funds Hold 6% Of Enanta As Hepatitis C Royalties Decline
- URL: https://www.bullished.co/adar1s-private-funds-hold-6-of-enanta-as-hepatitis-c-royalties-decline-a585614b/
- Published: 2026-11-17T03:16:12.000Z
- Updated: 2026-11-17T03:16:12.000Z
- Description: The adviser and its sole manager reported the same shares, while Enanta expects its cash to fund operations into fiscal 2029.
- Author: Matteo Parrino
- Tags: SEC Filings, ENTA, Industry: Healthcare

Private funds managed by ADAR1 Capital Management hold a [6% stake](https://www.sec.gov/Archives/edgar/data/0001940272/000110465926128729/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) in [Enanta Pharmaceuticals](https://www.bullished.co/tag/enta/), which develops small-molecule drugs for virology and immunology. The investment adviser reported the position as of September 30 in a passive ownership disclosure filed Monday, while Enanta's hepatitis C royalty revenue has declined.

## One Holding, Shared Voting Power

The position comprises 1,733,320 common shares directly owned by ADAR1's private investment funds. ADAR1 reported indirect beneficial ownership, meaning the shares are held through the funds it manages.

Daniel Schneeberger, ADAR1's sole manager, reported the same 1,733,320 shares and 6% interest. Both reporting persons have shared voting authority over that holding; the two entries describe the same fund-owned shares.

ADAR1 and Schneeberger certified that they bought and hold the securities in ordinary business without a purpose of changing or influencing Enanta's control. The reported percentage uses a base of [29,125,402 outstanding shares](https://www.sec.gov/Archives/edgar/data/0001940272/000110465926128729/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) as of August 7, 2026.

## Hepatitis C Revenue Falls

Enanta reported fiscal fourth-quarter revenue of [$12.9 million](https://markets.ft.com/data/announce/detail?dockey=600-202611161601BIZWIRE%5FUSPRX%5F%5F%5F%5F20261116%5FBW633822-1&ref=bullished.co), down from $15.1 million a year earlier, in its results announcement. All of that revenue came from worldwide sales of AbbVie's MAVYRET/MAVIRET hepatitis C treatment.

Enanta discovered glecaprevir, the antiviral AbbVie sells as part of that combination. Substantially all of Enanta's royalty revenue since August 2017 has come from the regimen, sold as MAVYRET in the U.S. and MAVIRET elsewhere across more than 50 countries.

Enanta recorded a [full-year loss](https://www.wusa9.com/article/syndication/associatedpress/enanta-pharmaceuticals-fiscal-q4-earnings-snapshot/616-5643aa7d-4302-4146-8538-3ba9cd34be7d?ref=bullished.co) of $68.2 million on revenue of $63 million.

## Cash Supports The RSV Pipeline

Enanta held $194.5 million in cash and marketable securities at September 30\. Management expects that money to support operations into fiscal 2029.

The company's own pipeline includes two clinical-stage candidates for respiratory syncytial virus, or RSV. It is also developing early-stage oral drugs for type 2 inflammatory diseases, including chronic spontaneous urticaria and atopic dermatitis.

Enanta expects results from its [mid-stage pediatric trial](https://markets.ft.com/data/announce/detail?dockey=600-202611161601BIZWIRE%5FUSPRX%5F%5F%5F%5F20261116%5FBW633822-1&ref=bullished.co) of the RSV drug zelicapavir in the first quarter of 2027.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [SCHEDULE 13G — ADAR1 Capital Management, LLC re: Enanta Pharmaceuticals Inc. (ENTA)](https://www.sec.gov/Archives/edgar/data/0001940272/000110465926128729/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR
- [Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2026 – Company Announcement - FT.com](https://markets.ft.com/data/announce/detail?dockey=600-202611161601BIZWIRE%5FUSPRX%5F%5F%5F%5F20261116%5FBW633822-1&ref=bullished.co) — Financial Times
- [Enanta Pharmaceuticals: Fiscal Q4 Earnings Snapshot | wusa9.com](https://www.wusa9.com/article/syndication/associatedpress/enanta-pharmaceuticals-fiscal-q4-earnings-snapshot/616-5643aa7d-4302-4146-8538-3ba9cd34be7d?ref=bullished.co) — Associated Press

### More on Enanta Pharmaceuticals

- [Enanta Expects $194.5 Million Plus Royalties To Fund Operations Into Fiscal 2029](https://www.bullished.co/enanta-expects-194-5-million-plus-royalties-to-fund-operations-into-fiscal-2029-b1983823/)
- [European Court Invalidates Enanta's Paxlovid Patent And Tosses Its Infringement Suit Against Pfizer](https://www.bullished.co/european-court-invalidates-enantas-paxlovid-patent-and-tosses-its-infringement-suit-d3d7ac22/)
- [Enanta Stock Plunges 9% As CEO Jay Luly Plans To Retire After 23 Years](https://www.bullished.co/enanta-stock-plunges-9-as-ceo-jay-luly-plans-to-retire-after-23-years-b48eb831/)

[All Enanta Pharmaceuticals (ENTA) coverage →](https://www.bullished.co/tag/enta/)